Novartis stock
NOVN.SWSIXNovartis AG, HealthcareISIN CH0012005267
76Score 76 out of 100, Strong
Price and trend
82 / 100
Price history
+28% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.8% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 68).
The price is at its 52-week high. Largest decline in 20 years: 47% (February 2007 to March 2009).
Chart figures for advanced users
- SMA 50$148.21
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$147.31
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)68
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$121.01
- The lowest closing price of the last twelve months.
- Resistance$162.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Novartis AG belongs to the Drug Manufacturers (General) industry (Switzerland) and, with a market value of $305.46B, is number 6 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $57.13B (up 10.4% year on year) and earnings of $14.65B (up 22.7%).
- MEQIRI Score 76 out of 100 (Strong): rank 58 of 714 in Healthcare, median 53.
Show more
- The P/E is 31 (Drug Manufacturers (General) median 25.6, own median of recent years 20.5).
- Our model puts fair value at $186.41, with the price 14% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 29 years.Capital allocation 83
- Share buybacksShare count down 15% since 2020.Capital allocation 83
- Earnings turn into cashFree cash flow 155% of earnings over the last 12 months.Fundamentals 95
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and profitability, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 75 to 76.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- very large company
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $155.35 and expensive above $233.02 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $239.24 (cash-flow model) and $133.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $166.15, at 7.8% it would be $216.84.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 2.5% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 31%, net 26%. Last 12 months: net 18%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 27 Oct 2026EPS reported 2.03 (expected 1.87)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 8.76−1.2%
- Revenue
- $56.47B−1.7%
- Earnings per share
- 9.75−1.3%
- Revenue
- $60.29B−1.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.4%Novartis raised its 2026 profit guidance, now expecting core operating income to be stable to slightly up instead of a slight decline, while confirming low single digit net sales growth.
“We now expect for the full year 2026, core operating income to be in line to growing low single digit. For reference, this is an upgrade from the previous guidance of core operating income of low single digit decline for the full year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
What happened at Novartis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Johnson & JohnsonJNJ $675.03B75
- AbbVieABBV $521.41B75
- Roche HoldingROP.SW $391.92B77
- MerckMRK $362.86B68
- AstraZenecaAZN $287.66B73
- AmgenAMGN $253.21B77
- Gilead SciencesGILD $210.52B58
- Novo NordiskNOVO-B.CO $178.97B79
ETFs that hold Novartis
Held by 154 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Switzerland UCITS ETF 1DXSMI | 15.58% | 0.30% | €2.88B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 15.10% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 15.08% | 0.18% | €954.9M |
Show 5 more
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 14.97% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 14.89% | 0.46% | €729.65M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 11.11% | 0.25% | €237.76M |
| iShares SLI UCITS ETF (DE)EXI1 | 9.83% | 0.51% | €589.04M |
| iShares STOXX Europe 600 Top 20 UCITS ETF (DE)EXW3 | 6.64% | 0.20% | €141.47M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 25 Apr 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.